Purpose and Background of Fundraising
Since its inception in 2016, Methuselah has been engaged in the research and development of new cell therapies for heart failure. Our lead asset, MTC001, is a cell therapy using VCAM1-positive cardiac fibroblasts (VCFs) and has confirmed favorable therapeutic effects, such as promoting regeneration of damaged heart tissue, in preclinical studies.
Through this financing, Methuselah will further strengthen its capacity to conduct Phase I clinical trials of MTC001, a cell therapy with a workflow that reduces the burden on medical institutions and a simple manufacturing process. By manufacturing from minimally invasive tissue harvested from the patient's own heart, MTC001 has a significant advantage over other technologies in terms of manufacturing and safety. The achievement of this financing is a major milestone for the future growth of the company, which will strongly promote the efficiency of the manufacturing process, creation of subsequent pipelines, and strategic alliances with academia and companies, with a view to global expansion.

UTEC Partner and Director Atsushi Usami comments:
We are pleased to support Methuselah at this time of its major expansion. Methuselah's approach to science and business, combined with its innovative technology, strong team, and UTEC's investment strategy of focusing on solving global human problems, make this the largest initial investment we have made to date. The speed of development of VCF, which until just five years ago was an academic project, has been phenomenal, and we look forward to working closely with the Methuselah team in the future."
Hiroaki Kobayashi, Principal, UTEC, comments:
As an emergency intensivist, I have treated numerous patients suffering from myocardial infarction and heart failure and have witnessed firsthand the devastating impact on patients, families, and society. Despite the increasing number of patients worldwide, treatment options remain limited and innovation beyond drug therapy is desperately needed. As Methuselah prepares to launch its first clinical trial in patients in early 2021, the timing is right to take a major step toward bringing an innovative product to market. We will continue to fully support Team Methuselah's challenge, believing that the company will be highly regarded not only in Japan but around the world."
Appointment of New Outside Corporate Auditors and Outside Directors
Atsushi Usami, a director and partner of UTEC, was newly appointed as an outside auditor, and Hiroaki Kobayashi, also a principal of UTEC, was appointed as an outside director.
About Atsushi Usami
He has been in charge of seed/early stage investments, mainly in the life science field, and has been a JST START project promoter, a NEDO TCP mentor, and a lecturer at the University of Tokyo's Life Innovation Leading Graduate School Colloquium on industry-academia collaboration. Prior to joining UTEC, he worked at Mitsubishi Research Institute, Inc.
About Hiroaki Kobayashi
After graduating from the University of Tokyo Faculty of Medicine, he worked as an emergency intensivist at the same university hospital and Hitachi General Hospital, Hitachi, Ltd. After working at Japan Organization for Medical Device Development (JOMDD), he studied at the University of Michigan Graduate School of Business Administration (MBA) as a Fulbright Scholar. After returning to Japan, he worked in the Business Development Division of a major medical device manufacturer before joining UTEC in August 2019.
List of underwriters for Series B-2 round (in no particular order)
The University of Tokyo Edge Capital Partners
Alfresa Corporation
The Dai-ichi Life Insurance Co.
KSP Corporation
MAKOTO CAPITAL
Overview of Series B-2 Underwriters
<The University of Tokyo Edge Capital Partners Outline
The University of Tokyo Edge Capital Corporation/University of Tokyo Edge Capital Partners (UTEC) is a venture capital firm that invests in venture companies that utilize the outstanding intellectual property and human resources of the University of Tokyo and other universities and research institutions. Since 2004, UTEC has established and managed four venture capital funds (totaling approximately 55 billion yen as of December 2020), supporting startups based on science and advanced technology, including those from the University of Tokyo.
<Outline of Alfresa Corporation
Alfresa has a social mission to deliver "safe, secure, and high-quality" pharmaceuticals and other products needed when, in the quantities, and to the places where they are needed. Within the Alfresa Group, which has a distribution platform covering all of Japan, there are approximately 180 sales offices in Hokkaido, Tokyo, Nagoya, Osaka, Koshinetsu, and Kyushu, and a total of 2,000 pharmaceutical and medical sales representatives and medical engineers are engaged in sales activities to medical institutions. In addition to a "full lineup" of almost all domestic and overseas manufacturers of pharmaceuticals, reagents, and medical devices, and a "thorough quality control and safe and secure delivery system" to support this lineup, the company is working to respond flexibly and immediately to diverse needs through its high-quality "information provision capabilities.
<Outline of Dai-ichi Life Insurance Co.
The Dai-ichi Life Insurance Company, Limited, was founded in 1902 as Japan's first mutual company. Since then, the company has constantly challenged itself to make changes for the benefit of its customers and society, including becoming the first major life insurance company in Japan to be incorporated as a joint stock company in 2010, and transitioning to a holding company structure in 2016. The company also has an aspect of being an institutional investor, managing approximately 36 trillion yen in assets. In light of the liability characteristics of life insurance policies, the company is actively promoting ESG investments with the aim of both improving investment profitability and resolving social issues, while maintaining its basic ALM approach, which focuses on fixed-income assets. As part of its ESG investment activities, the company is actively making impact investments in venture companies in fields that are highly compatible with its life insurance business, such as medical, healthcare, and fintech, with the aim of both generating investment income and creating a social impact.
<Outline of KSP Inc.
KSP Corporation, the core of the Kanagawa Science Park (KSP), is working to create new industries through the fostering and incubation of venture companies. The company provides support according to growth stage at each stage from start-up to business growth and IPO, and promotes business development that promotes the production of high value-added venture companies that meet the needs of the times. KSP's funds invest in high-tech ventures that are expected to grow rapidly, mainly in the early stages. The current investment in Methuselah Corporation is being made from KSP6 Investment Limited Partnership, which was formed in January 2020.
<Outline of MAKOTO CAPITAL
MAKOTO Capital is a professional firm within the MAKOTO Group, a business creation company based in Sendai City. Under the slogan of "Growth from Tohoku," MAKOTO Capital currently operates a fund business, an accelerator business, and a management consulting business. MAKOTO CAPITAL's overriding mission is to build an ecosystem of business creation and growth in Tohoku by supporting entrepreneurs and companies operating in the region, and to create a Tohoku that can be proud to be part of the world.
About MTC001
MTC001 is a combination product that combines autologous cardiac fibroblasts (VCAM1-positive cardiac fibroblasts, VCF) with a novel catheter for administration. This product has two major advantages over other cell therapies: (1) it is an autologous cell and is organ-derived, making it ideal for highly immune-responsive organs such as the heart, and (2) the minimally invasive catheter specifically designed for VCF administration ensures reliable and safe delivery of cells.
| name of company | Methuselah Corporation |
| Establishment | March 2016 |
| capital stock | Tsuruoka City, Yamagata Prefecture |
| representative | Takahiro Iwamiya, Kenichi Nogami |
| Business Overview | Research and development of treatment methods for heart disease using fibroblasts |
| uniform resouce locator | https://www.metcela.com/ |








